ארצות הברית - אנגלית - NLM (National Library of Medicine)

american health packaging - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 10 mg - nifedipine capsules, usp are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. nifedipine capsules, usp are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers an

ארצות הברית - אנגלית - NLM (National Library of Medicine)

golden state medical supply, inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 10 mg - i. vasospastic angina nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. ii. chronic stable angina (classical effort-associated angina) nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain

ארצות הברית - אנגלית - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 10 mg - i. vasospastic angina nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. ii. chronic stable angina (classical effort-associated angina) nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain

ארצות הברית - אנגלית - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 10 mg - i. vasospastic angina nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. ii. chronic stable angina (classical effort-associated angina) nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain

ארצות הברית - אנגלית - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions: drug interactions.) nifedipine must not be used in cases of cardiogenic shock. nifedipine is contraindicated in patients with a known hypersensitivity to any component of the tablet.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

onelink - nifedipine 30mg;  ;   - modified release tablet - 30 mg - active: nifedipine 30mg     excipient: carbomer 934p colloidal silicon dioxide hypromellose   iron oxide red lactose monohydrate macrogol 4000 magnesium stearate   methacrylic acid copolymer povidone purified talc   titanium dioxide - treatment of mild to moderate hypertension.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - nifedipine 60mg;  ;   - modified release tablet - 60 mg - active: nifedipine 60mg     excipient: carbomer 934p colloidal silicon dioxide hypromellose   iron oxide red lactose monohydrate macrogol 4000 magnesium stearate   methacrylic acid copolymer povidone purified talc   titanium dioxide - treatment of mild to moderate hypertension.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

bryant ranch prepack - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - adalat® cc is an extended release tablet dosage form of the calcium channel blocker nifedipine. nifedipine is 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-dimethyl ester, c17 h18 n2 o6 , and has the structural formula: nifedipine is a yellow crystalline substance, practically insoluble in water but soluble in ethanol. it has a molecular weight of 346.3. adalat cc tablets consist of an external coat and an internal core. both contain nifedipine, the coat as a slow release formulation and the core as a fast release formulation. adalat cc tablets contain either 30, 60, or 90 mg of nifedipine for once-a-day oral administration. inert ingredients in the formulation are: hydroxypropylcellulose, lactose, corn starch, crospovidone, microcrystalline cellulose, silicon dioxide, and magnesium stearate. the inert ingredients in the film coating are: hypromellose, polyethylene glycol, ferric oxide, and titanium dioxide.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atenolol, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; sodium starch glycollate type a; colloidal anhydrous silica; maize starch; sodium lauryl sulfate; magnesium stearate; hypromellose; macrogol 6000; titanium dioxide; purified talc - atenolol is indicated in the management of:,(i) all grades of hypertension, including hypertension of renal origin. (ii) frequent disabling angina without evidence of cardiac failure. (iii) cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those associated with acute myocardial infarction), (iv) myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atenolol, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; sodium starch glycollate type a; colloidal anhydrous silica; maize starch; sodium lauryl sulfate; magnesium stearate; hypromellose; macrogol 6000; titanium dioxide; purified talc - atenolol is indicated in the management of:,(i) all grades of hypertension, including hypertension of renal origin. (ii) frequent disabling angina without evidence of cardiac failure. (iii) cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those associated with acute myocardial infarction), (iv) myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)